RSPO1 and cancer: Increased WNT signaling activity resulting from elevated cell surface levels of WNT receptors, such as through loss-of-function mutations of Wnt receptor-specific ubiquitin ligases ZNRF3 and RNF43 (2) and recurrent R-spondin (RSPO) fusion proteins (3), has also been documented in a number of cancers.